Under the terms of the amended agreement, Allergan will be responsible for the registration of the compound in the newly licensed territories, state news wire MTI reported. Allergan will also pay tiered net sales related royalties to Richter.

“We are very pleased to further increase the geographic coverage of cariprazine for schizophrenia, bipolar I disorder and bipolar depression, providing an innovative treatment for patients suffering from such a complex condition as the spectrum disease,” said Richter CEO Gábor Orbán.

Cariprazine was Richterʼs third best-selling drug last year, after contraceptives and the nootropic Cavinton.